Diabetes drug company Sanofi-Aventis has made it clear that a final-stage study on its new type 2 diabetes drug has proved successful. The Phase III clinical trial results indicate that the drug, lixisentide, improve glycaemic control amongst patients with type 2 diabetes . The drug also reduces glucose in blood cells.
The drug will be part of the new diabetes drug class of GLP-1 inhibitors . Rivals in the class include Amylin, Byetta and Victoza . Some analysts claim that the drug is late to the field, but this remains to be seen.
The drug represents an attempt to broaden its diabetes offering, which currently includes blockbuster insulin Lantus . The new Sanofi diabetes division are trying to make the company more competitive in the fight against the disease. Marc Cluzel of Sanofi reportedly commented: "Developing new diabetes treatments, like lixisenatide, and helping patients achieve diabetes control is paramount to tackling the growing diabetes epidemic ."
Diabetes drug study positive according to Sanofi
Fri, 16 Apr 2010
Recommended links
Diabetes forumDiabetes charities
Diabetes myLifestyle
Diabetes food and recipes
Diabetes pensions and annuities
Diabetes ID alert wristband
The Diet Plate to help control diabetes
Diabetes drug distribution suspended in Saudi Arabia
Diabetes management system approved by Food and Drug Administration
Food and Drug Administration call for more information on Amylin diabetes drug
Supporters of diabetes drug had financial ties to pharmaceutical company
Diabetes injection Byetta LAR faces Food and Drug Administration decision
GlaxoSmithKline defends diabetes drug Avandia
Patient concern over diabetes drug Avandia
Food and Drug Administration say diabetes patients should not stop taking Avandia
Popular Cholesterol drugs increase diabetes risk
Smell of fish may put patients off diabetes drug
24 hour Diabetes drug Victoza approved for National Health Service use
Diabetes drug could cut body mass index
Weight loss drug alli could reduce dangerous diabetes fat
Type 2 diabetes drug gets Food and Drug Administration approval
Join us